Simon Witzel
Overview
Explore the profile of Simon Witzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiesenfarth M, Forouhideh-Wiesenfarth Y, Elmas Z, Parlak O, Weiland U, Herrmann C, et al.
J Neurol
. 2025 Mar;
272(4):259.
PMID: 40056187
No abstract available.
2.
Kassubek J, Roselli F, Witzel S, Dorst J, Ludolph A, Rasche V, et al.
Sci Rep
. 2025 Jan;
15(1):1551.
PMID: 39789167
Primary lateral sclerosis (PLS) is a motor neuron disease (MND) which mainly affects upper motor neurons. Within the MND spectrum, PLS is much more slowly progressive than amyotrophic laterals sclerosis...
3.
Witzel S, Huss A, Nagel G, Rosenbohm A, Rothenbacher D, Peter R, et al.
Ann Neurol
. 2024 Aug;
96(6):1040-1057.
PMID: 39177232
Objective: Neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains (pNfH), established as diagnostic and prognostic biomarkers in hospital-based amyotrophic lateral sclerosis (ALS) cohorts, are now surrogate markers in clinical...
4.
Wiesenfarth M, Forouhideh-Wiesenfarth Y, Elmas Z, Parlak O, Weiland U, Herrmann C, et al.
J Neurol
. 2024 Aug;
271(10):6667-6679.
PMID: 39141064
Pathogenic variants in the Cu/Zn superoxide dismutase (SOD1) gene can be detected in approximately 2% of sporadic and 11% of familial amyotrophic lateral sclerosis (ALS) patients in Europe. We analyzed...
5.
Witzel S, Micca V, Muller H, Huss A, Bachhuber F, Dorst J, et al.
J Neurol Neurosurg Psychiatry
. 2024 Feb;
95(8):737-747.
PMID: 38388486
Background: Validation of the 2020 consensus criteria for primary lateral sclerosis (PLS) is essential for their use in clinical practice and future trials. Methods: In a large cohort of patients...
6.
Wiesenfarth M, Dorst J, Brenner D, Elmas Z, Parlak O, Uzelac Z, et al.
EClinicalMedicine
. 2024 Feb;
69:102495.
PMID: 38384337
Background: In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of -amyotrophic lateral sclerosis (ALS), after a decrease of neurofilament...
7.
Schuster J, Dreyhaupt J, Monkemoller K, Dupuis L, Dieterle S, Weishaupt J, et al.
Eur J Neurol
. 2024 Jan;
31(4):e16204.
PMID: 38240416
Background And Purpose: In 2016, we concluded a randomized controlled trial testing 1 mg rasagiline per day add-on to standard therapy in 252 amyotrophic lateral sclerosis (ALS) patients. This article...
8.
Witzel S, Statland J, Steinacker P, Otto M, Dorst J, Schuster J, et al.
Eur J Neurol
. 2023 Nov;
31(3):e16154.
PMID: 37975796
Background And Purpose: Rasagiline might be disease modifying in patients with amyotrophic lateral sclerosis (ALS). The aim was to evaluate the effect of rasagiline 2 mg/day on neurofilament light chain...
9.
Ramachandran S, Grozdanov V, Leins B, Kandler K, Witzel S, Mulaw M, et al.
Front Immunol
. 2023 Aug;
14:1193507.
PMID: 37545536
Background: Dysregulation of the immune system in amyotrophic lateral sclerosis (ALS) includes changes in T-cells composition and infiltration of T cells in the brain and spinal cord. Recent studies have...
10.
Kuhlwein J, Ruf W, Kandler K, Witzel S, Lang C, Mulaw M, et al.
Cell Mol Life Sci
. 2023 Apr;
80(5):131.
PMID: 37095391
Amyotrophic Lateral Sclerosis (ALS) is a complex and incurable neurodegenerative disorder in which genetic and epigenetic factors contribute to the pathogenesis of all forms of ALS. The interplay of genetic...